238 related articles for article (PubMed ID: 11860442)
1. FAB M4 and high CD14 surface expression is associated with high cellular resistance to Ara-C and daunorubicin: implications for clinical outcome in acute myeloid leukaemia.
Nørgaard JM; Olesen LH; Olesen G; Meyer K; Kristensen JS; Bendix K; Pedersen B; Kjeldsen E; Hokland P
Eur J Haematol; 2001 Oct; 67(4):221-9. PubMed ID: 11860442
[TBL] [Abstract][Full Text] [Related]
2. Pretreatment leukaemia cell drug resistance is correlated to clinical outcome in acute myeloid leukaemia.
Nørgaard JM; Langkjer ST; Palshof T; Pedersen B; Hokland P
Eur J Haematol; 2001 Mar; 66(3):160-7. PubMed ID: 11350484
[TBL] [Abstract][Full Text] [Related]
3. Leukaemia cell drug resistance and prognostic factors in AML.
Nørgaard JM; Olesen G; Kristensen JS; Pedersen B; Hokland P
Eur J Haematol; 1999 Oct; 63(4):219-24. PubMed ID: 10530409
[TBL] [Abstract][Full Text] [Related]
4. Relation of blast cell survival and proliferation to chemotherapy resistance in AML.
Nørgaard JM; Langkjer ST; Palshof T; Clausen N; Pedersen B; Hokland P
Br J Haematol; 1996 Jun; 93(4):888-97. PubMed ID: 8703822
[TBL] [Abstract][Full Text] [Related]
5. P-glycoprotein expression and prognostic value in acute myeloid leukemia.
Senent L; Jarque I; Martín G; Sempere A; González-García Y; Gomis F; Pérez-Sirvent M; De La Rubia J; Sanz MA
Haematologica; 1998 Sep; 83(9):783-7. PubMed ID: 9825574
[TBL] [Abstract][Full Text] [Related]
6. MDR1 gene expression and drug resistance of AML cells.
Nørgaard JM; Bukh A; Langkjer ST; Clausen N; Palshof T; Hokland P
Br J Haematol; 1998 Mar; 100(3):534-40. PubMed ID: 9504636
[TBL] [Abstract][Full Text] [Related]
7. Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry.
Guerci A; Merlin JL; Missoum N; Feldmann L; Marchal S; Witz F; Rose C; Guerci O
Blood; 1995 Apr; 85(8):2147-53. PubMed ID: 7536492
[TBL] [Abstract][Full Text] [Related]
8. Long-term survival and development of secondary malignancies in patients with acute myeloid leukemia treated with aclarubicin or daunorubicin plus cytosine arabinoside followed by intensive consolidation chemotherapy in a Danish national phase III trial. Danish Society of Haematology Study Group on AML.
de Nully Brown P; Hoffmann T; Hansen OP; Boesen AM; Grønbaek K; Hippe E; Jensen MK; Thorling K; Storm HH; Pedersen-Bjergaard J
Leukemia; 1997 Jan; 11(1):37-41. PubMed ID: 9001416
[TBL] [Abstract][Full Text] [Related]
9. [The current chemotherapy of acute myeloid leukemias in adults].
Poddubnaia IV; Perilov AA
Ter Arkh; 1993; 65(7):86-9. PubMed ID: 8211791
[No Abstract] [Full Text] [Related]
10. A systematic overview of chemotherapy effects in acute myeloid leukaemia.
Kimby E; Nygren P; Glimelius B;
Acta Oncol; 2001; 40(2-3):231-52. PubMed ID: 11441935
[TBL] [Abstract][Full Text] [Related]
11. In vitro resistance to cytosine arabinoside, not to daunorubicin, is associated with the risk of relapse in de novo acute myeloid leukaemia.
Klumper E; Ossenkoppele GJ; Pieters R; Huismans DR; Loonen AH; Rottier A; Westra G; Veerman AJ
Br J Haematol; 1996 Jun; 93(4):903-10. PubMed ID: 8703824
[TBL] [Abstract][Full Text] [Related]
12. Effect on cell kill of addition of multidrug resistance modifiers cyclosporin A and PSC 833 to cytotoxic agents in acute myeloid leukaemia.
Grey M; Borg AG; Wood P; Burgess R; Fisher A; Yin JA
Leuk Res; 1997 Sep; 21(9):867-74. PubMed ID: 9393602
[TBL] [Abstract][Full Text] [Related]
13. Low L-selectin (CD62L) expression in acute myeloid leukemia correlates with a bad cytogenetic risk.
Graf M; Reif S; Hecht K; Pelka-Fleischer R; Pfister K; Nuessler V; Schmetzer H
Eur J Haematol; 2003 Nov; 71(5):366-76. PubMed ID: 14667200
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of surface antigen expression in children with acute myeloid leukemia: results of study AML-BFM-87.
Creutzig U; Harbott J; Sperling C; Ritter J; Zimmermann M; Löffler H; Riehm H; Schellong G; Ludwig WD
Blood; 1995 Oct; 86(8):3097-108. PubMed ID: 7579404
[TBL] [Abstract][Full Text] [Related]
15. Anthracycline drugs and MDR expression in human leukemia.
Pogliani EM; Belotti D; Rivolta GF; Maffè PF; Corneo G
Cytotechnology; 1996; 19(3):229-35. PubMed ID: 8862011
[TBL] [Abstract][Full Text] [Related]
16. The prognostic value of cytogenetics is reinforced by the kind of induction/consolidation therapy in influencing the outcome of acute myeloid leukemia--analysis of 848 patients.
Visani G; Bernasconi P; Boni M; Castoldi GL; Ciolli S; Clavio M; Cox MC; Cuneo A; Del Poeta G; Dini D; Falzetti D; Fanin R; Gobbi M; Isidori A; Leoni F; Liso V; Malagola M; Martinelli G; Mecucci C; Piccaluga PP; Petti MC; Rondelli R; Russo D; Sessarego M; Specchia G; Testoni N; Torelli G; Mandelli F; Tura S
Leukemia; 2001 Jun; 15(6):903-9. PubMed ID: 11417475
[TBL] [Abstract][Full Text] [Related]
17. Current strategies for treatment of acute myeloid leukemia at St Jude Children's Research Hospital.
Hurwitz CA; Krance R; Schell MJ; Santana VM; Brenner MK; Ribeirio R; Roberts WM; Mahmoud H; Belt J; Crom W
Leukemia; 1992; 6 Suppl 2():39-43. PubMed ID: 1374492
[TBL] [Abstract][Full Text] [Related]
18. Cellular drug resistance profiles in childhood acute myeloid leukemia: differences between FAB types and comparison with acute lymphoblastic leukemia.
Zwaan CM; Kaspers GJ; Pieters R; Ramakers-Van Woerden NL; den Boer ML; Wünsche R; Rottier MM; Hählen K; van Wering ER; Janka-Schaub GE; Creutzig U; Veerman AJ
Blood; 2000 Oct; 96(8):2879-86. PubMed ID: 11023525
[TBL] [Abstract][Full Text] [Related]
19. Functional multidrug resistance phenotype associated with combined overexpression of Pgp/MDR1 and MRP together with 1-beta-D-arabinofuranosylcytosine sensitivity may predict clinical response in acute myeloid leukemia.
Schuurhuis GJ; Broxterman HJ; Ossenkoppele GJ; Baak JP; Eekman CA; Kuiper CM; Feller N; van Heijningen TH; Klumper E; Pieters R
Clin Cancer Res; 1995 Jan; 1(1):81-93. PubMed ID: 9815890
[TBL] [Abstract][Full Text] [Related]
20. Clinical relevance of in vitro chemoresistance in childhood acute myeloid leukemia.
Yamada S; Hongo T; Okada S; Watanabe C; Fujii Y; Ohzeki T
Leukemia; 2001 Dec; 15(12):1892-7. PubMed ID: 11753610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
